Supplementary Material for: Characterization and Outcomes of Disease Progression in 52 Patients Treated with <b><i>BRAF</i></b>-V600 + MEK Inhibitors for Advanced Melanoma

<b><i>Background:</i></b> Combined treatment with <i>BRAF</i>-V600 and MEK inhibitors has significantly improved progression-free and overall survival of patients with <i>BRAF</i>-mutated melanoma. Pattern of disease progression and outcomes in patients have not been fully characterized. <b><i>Methods:</i></b> We conducted a single-center, retrospective, descriptive analysis of a cohort of 52 patients treated with <i>BRAF</i>-V600 + MEK inhibitors for advanced melanoma over a 12-month period. The aim of this study was to characterize disease progression, defined as metastatic pattern, disease kinetics, and response to subsequent therapies, in melanoma patients treated with <i>BRAF</i>-V600 + MEK inhibitors. <b><i>Results:</i></b> Disease progression was observed in 31/52 (59.6%) patients treated with <i>BRAF</i>-V600 + MEK inhibitors. Relapse of melanoma involved the CNS for 22/31 (70.9%) patients with disease progression, including 18/31 (58%) patients who had exclusive intracranial metastases. Sixteen patients died from disease progression. Among the 31 patients who had disease progression, the median time until a relapse was 8 months, and the median survival time after disease progression was 2 months. <b><i>Conclusion:</i></b> Our study shows that, for patients treated with <i>BRAF</i>-V600 + MEK inhibitors who lose response, disease progression was aggressive and had poor outcomes. Most patients had CNS metastases and low rates of therapeutic response to any subsequent therapy.